Targeting Gut Microbiota As a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Aug 26

PMID 36009566

Authors

Oxana M Drapkina

Adel A Yafarova

Anastasia N Kaburova

Anton R Kiselev

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) remain the major public health concern worldwide. Over the last two decades, a considerable amount of literature has been published on gut microbiota (GMB) composition and its metabolites, involved in the pathophysiology of CVDs, including arterial hypertension, atrial fibrillation, and congestive heart failure. Although many types of medicines are available to treat CVD, new therapeutic tools are needed to improve clinical outcomes. A challenge that often arises in the researchers' community is how to manipulate the GMB to manage cardiovascular risk factors. Therapeutic strategies designed to manipulate GMB composition and/or its metabolites include dietary approaches, prebiotics/probiotics supplementation, and fecal microbiota transplantation (FMT). In this review, we have focused on three main cardiovascular pathologies (arterial hypertension, atrial fibrillation and heart failure) due to their shared common pathophysiological pathways and structural changes in myocardium, such as inflammation, hypertrophy, fibrosis, and myocardial remodeling. The main aims of the review are: (1) to summarize current knowledge on the key pathophysiologic links between GMB and CVDs, and (2) discuss the results of the studies on GMB modulation for the prevention and treatment of selected CVDs.

Citing Articles

Intestinal Microbiota and Derived Metabolites in Myocardial Fibrosis and Postoperative Atrial Fibrillation.

Nenna A, Laudisio A, Taffon C, Fogolari M, Spadaccio C, Ferrisi C Int J Mol Sci. 2024; 25(11).

PMID: 38892223 PMC: 11173100. DOI: 10.3390/ijms25116037.

Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease.

Lakhanpal S, Aggarwal K, Kaur H, Kanwar K, Gupta V, Bhavsar J Intest Res. 2024; 23(1):23-36.

PMID: 38712363 PMC: 11834363. DOI: 10.5217/ir.2023.00104.

Trends in gut-heart axis and heart failure research (1993-2023): A bibliometric and visual analysis.

Ouyang J, Zhao L, Song Y, Qu H, Du T, Shi L Heliyon. 2024; 10(4):e25995.

PMID: 38404792 PMC: 10884449. DOI: 10.1016/j.heliyon.2024.e25995.

The Role of Gut Microbiota and the Potential Effects of Probiotics in Heart Failure.

Petruzziello C, Saviano A, Manetti L, Macerola N, Ojetti V Medicina (Kaunas). 2024; 60(2).

PMID: 38399558 PMC: 10890346. DOI: 10.3390/medicina60020271.

Relationships among gut microbes, the interleukin family, and hypertension: a mediation Mendelian randomization study.

Zhao S, Zhang J, Ding F, Sun S Front Nutr. 2023; 10:1293170.

PMID: 38089928 PMC: 10714948. DOI: 10.3389/fnut.2023.1293170.

References

Yang W, Zhang S, Zhu J, Jiang H, Jia D, Ou T . Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis. J Mol Cell Cardiol. 2019; 134:119-130. DOI: 10.1016/j.yjmcc.2019.07.004. View

Sun S, Lulla A, Sioda M, Winglee K, Wu M, Jacobs Jr D . Gut Microbiota Composition and Blood Pressure. Hypertension. 2019; 73(5):998-1006. PMC: 6458072. DOI: 10.1161/HYPERTENSIONAHA.118.12109. View

Farnworth E, Mainville I, Desjardins M, GARDNER N, Fliss I, Champagne C . Growth of probiotic bacteria and bifidobacteria in a soy yogurt formulation. Int J Food Microbiol. 2007; 116(1):174-81. DOI: 10.1016/j.ijfoodmicro.2006.12.015. View

Gil-Cruz C, Perez-Shibayama C, De Martin A, Ronchi F, Van der Borght K, Niederer R . Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019; 366(6467):881-886. DOI: 10.1126/science.aav3487. View

Costa C, Sampaio-Maia B, Araujo R, Nascimento D, Ferreira-Gomes J, Pestana M . Gut Microbiome and Organ Fibrosis. Nutrients. 2022; 14(2). PMC: 8781069. DOI: 10.3390/nu14020352. View

Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P . Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review. Ann Intern Med. 2017; 167(1):34-39. DOI: 10.7326/M16-2810. View

Aoyagi Y, Park S, Matsubara S, Honda Y, Amamoto R, Kushiro A . Habitual intake of fermented milk products containing Lactobacillus casei strain Shirota and a reduced risk of hypertension in older people. Benef Microbes. 2016; 8(1):23-29. DOI: 10.3920/BM2016.0135. View

Pluznick J, Protzko R, Gevorgyan H, Peterlin Z, Sipos A, Han J . Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013; 110(11):4410-5. PMC: 3600440. DOI: 10.1073/pnas.1215927110. View

Toral M, Robles-Vera I, de la Visitacion N, Romero M, Sanchez M, Gomez-Guzman M . Role of the immune system in vascular function and blood pressure control induced by faecal microbiota transplantation in rats. Acta Physiol (Oxf). 2019; 227(1):e13285. DOI: 10.1111/apha.13285. View

10.

Zhang Y, Zhang S, Li B, Luo Y, Gong Y, Jin X . Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome. Cardiovasc Res. 2021; 118(3):785-797. DOI: 10.1093/cvr/cvab114. View

11.

Khot U, Khot M, Bajzer C, Sapp S, Ohman E, Brener S . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290(7):898-904. DOI: 10.1001/jama.290.7.898. View

12.

Tang W, Li D, Hazen S . Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2018; 16(3):137-154. PMC: 6377322. DOI: 10.1038/s41569-018-0108-7. View

13.

Asgharzadeh F, Bargi R, Hosseini M, Farzadnia M, Khazaei M . Cardiac and renal fibrosis and oxidative stress balance in lipopolysaccharide-induced inflammation in male rats. ARYA Atheroscler. 2018; 14(2):71-77. PMC: 6087628. DOI: 10.22122/arya.v14i2.1550. View

14.

Pastori D, Carnevale R, Nocella C, Novo M, Santulli M, Cammisotto V . Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. J Am Heart Assoc. 2017; 6(6). PMC: 5669181. DOI: 10.1161/JAHA.117.005784. View

15.

Chen W, Chen Y, Hsieh M, Huang S, Kao Y, Chen Y . The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis. J Cardiovasc Electrophysiol. 2014; 26(2):203-10. DOI: 10.1111/jce.12554. View

16.

Melgaard L, Gorst-Rasmussen A, Lane D, Rasmussen L, Larsen T, Lip G . Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA. 2015; 314(10):1030-8. DOI: 10.1001/jama.2015.10725. View

17.

Yu L, Meng G, Huang B, Zhou X, Stavrakis S, Wang M . A potential relationship between gut microbes and atrial fibrillation: Trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation. Int J Cardiol. 2018; 255:92-98. DOI: 10.1016/j.ijcard.2017.11.071. View

18.

Kaye D, Shihata W, Jama H, Tsyganov K, Ziemann M, Kiriazis H . Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease. Circulation. 2020; 141(17):1393-1403. DOI: 10.1161/CIRCULATIONAHA.119.043081. View

19.

Taylor C, Ordonez-Mena J, Roalfe A, Lay-Flurrie S, Jones N, Marshall T . Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019; 364:l223. PMC: 6372921. DOI: 10.1136/bmj.l223. View

20.

Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F . Pathogenic Gut Flora in Patients With Chronic Heart Failure. JACC Heart Fail. 2015; 4(3):220-7. DOI: 10.1016/j.jchf.2015.10.009. View